US EditionPublished • loading... • Updated
Could a Novo error set up early GLP-1 generics in Canada?
- Novo Nordisk is advancing amycretin formulations to phase 3 development for weight management based on completed clinical studies and regulatory feedback.
- Results from a phase 1b/2a trial showed treatment-emergent adverse events were mild to moderate, increasing with dosage.
- Participants receiving amycretin had significantly greater weight loss compared to the placebo group.
- Further evaluation with more participants is needed to confirm the full efficacy of oral amycretin on weight reduction and metabolic changes.
Insights by Ground AI
69 Articles
69 Articles
Bennington Banner+66 Reposted by 66 other sources
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2
54-year-old Claus Heine went blind overnight - and he will never regain his sight. Now his rare eye disease has been linked to Novo Nordisk's popular weight loss drugs. The Danish drugmaker, contrary to authorities, maintains that there is no connection.
Coverage Details
Total News Sources69
Leaning Left8Leaning Right8Center20Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 22%
C 56%
R 22%
Factuality
To view factuality data please Upgrade to Premium
